At the European Society of Medical Oncology (ESMO) Congress held in Madrid, the capital of Spain, Uğur Şahin and Özlem Türeci, founders of the biotechnology company Biontech, announced that the first results of the cancer vaccine they have been working on for 15 years are promising. In the first results obtained from CARVac, the cancer vaccine developed by Biontech, it was announced that it could stop the growth of tumors and even shrink them.
WHAT ARE THE SIDE EFFECTS?
It was stated that the vaccine was administered in four doses to 44 patients and the tumors shrank by at least 30 percent in 59 percent of the subjects. It was stated that in 95 percent of the subjects, the cancer became stable and stopped growing after the vaccine.
It was stated that a dose-dependent increase in inflammatory reactions was observed in 23 of the subjects during the vaccine administration, and side effects such as low blood pressure and increased fever were observed in the subjects.
Biontech aims to treat approximately 10 thousand cancer patients by 2030. (UAV)
